Want to see TSE:PHRM full AI Analyst Report?
PHRM Stock Chart & Stats
C$0.10
C$0.00(0.00%)
At close: 4:00 PM EST
C$0.10
C$0.00(0.00%)
Day’s Range― - ―
52-Week RangeC$0.05 - C$0.77
Previous CloseN/A
Volume18.00K
Average Volume (3M)158.34K
Market Cap
C$5.01M
Enterprise ValueC$4.21M
Total Cash (Recent Filing)C$1.04M
Total Debt (Recent Filing)C$0.00
Price to Earnings (P/E)―
Beta-0.25
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding91,019,066
10 Day Avg. Volume117,358
30 Day Avg. Volume158,340
Financial Highlights & Ratios
PEG Ratio0.24
Price to Book (P/B)16.46
Price to Sales (P/S)0.00
P/FCF Ratio-13.24
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.04
Revenue Forecast (FY)C$83.60M
Bulls Say, Bears Say
Bulls Say
Low Leverage / No DebtHaving no reported debt materially reduces financial risk for a pre-revenue R&D firm. It lowers fixed obligations and interest pressure, preserving strategic optionality and making future financing or partnerships less constrained by leverage over the next several quarters.
Improving Loss ProfileA meaningful reduction in net losses and burn signals stronger cost control and operational discipline. For a development-stage biotech, a shrinking loss trajectory extends runway per capital raised and reduces near-term funding pressure if the trend persists across the next 2-6 months.
Specialized IP And Market FocusConcentrated expertise in ketamine/psychedelic therapeutics and delivery IP provides differentiated assets and higher barriers to entry. This structural positioning supports licensing, strategic partnerships, and niche commercial opportunities if clinical progress continues.
Bears Say
Pre-revenue Business ModelThe company generates no commercial revenue and relies on R&D timelines. Without product sales, ongoing negative operating and free cash flow means sustainability depends on external funding and successful clinical milestones, raising execution and financing risk.
Shrinking Equity CushionA rapidly reduced equity base weakens the balance sheet's ability to absorb setbacks and increases the likelihood of dilutive capital raises. Over a multi-quarter horizon, a thin equity cushion limits flexibility and heightens vulnerability to adverse trial or funding outcomes.
Weak Cash Generation; Financing RelianceNegative operating and free cash flows, despite improvement, mean the company will likely need new capital to advance programs. Dependence on external financing exposes the business to market conditions and potential dilution, constraining long-term strategy and stability.
PharmaTher Holdings Ltd News
PHRM FAQ
What was PharmaTher Holdings Ltd’s price range in the past 12 months?
PharmaTher Holdings Ltd lowest stock price was C$0.05 and its highest was C$0.77 in the past 12 months.
What is PharmaTher Holdings Ltd’s market cap?
PharmaTher Holdings Ltd’s market cap is C$5.01M.
When is PharmaTher Holdings Ltd’s upcoming earnings report date?
PharmaTher Holdings Ltd’s upcoming earnings report date is Sep 24, 2026 which is in 86 days.
How were PharmaTher Holdings Ltd’s earnings last quarter?
PharmaTher Holdings Ltd released its earnings results on Jan 30, 2026. The company reported -C$0.003 earnings per share for the quarter, missing the consensus estimate of N/A by -C$0.003.
Is PharmaTher Holdings Ltd overvalued?
According to Wall Street analysts PharmaTher Holdings Ltd’s price is currently Overvalued.
Does PharmaTher Holdings Ltd pay dividends?
PharmaTher Holdings Ltd does not currently pay dividends.
What is PharmaTher Holdings Ltd’s EPS estimate?
PharmaTher Holdings Ltd’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PharmaTher Holdings Ltd have?
PharmaTher Holdings Ltd has 91,019,066 shares outstanding.
What happened to PharmaTher Holdings Ltd’s price movement after its last earnings report?
PharmaTher Holdings Ltd reported an EPS of -C$0.003 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PharmaTher Holdings Ltd?
Currently, no hedge funds are holding shares in TSE:PHRM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PharmaTher Holdings Ltd
PharmaTher Holdings Ltd. operates as a clinical-stage biotechnology firm, primarily focused on psychedelic compounds. It is dedicated to investigating, advancing, and bringing to market innovative applications, formulations, and administration techniques for psychedelics to treat a range of conditions including mental health disorders, neurological ailments, and chronic pain. A key asset in its development portfolio is an intravenous ketamine injection, currently undergoing Phase II and III clinical evaluations targeting indications such as Parkinson's disease, anesthesia/sedation, and amyotrophic lateral sclerosis (ALS). The company's pipeline further features a Ketamine Patch, which is progressing through Phase I and II clinical trials for the treatment of depression, various mental health conditions, complex regional pain syndrome (CRPS), and other pain-related disorders. Additionally, a Ketamine Pump is undergoing Phase II clinical assessment for use in mental health, pain management, and surgical/procedural settings. Beyond these, PharmaTher is actively developing PHARMAPATCH, an innovative microneedle patch designed for psychedelic drug delivery. The company has established strategic collaboration agreements with several partners, including LTS Lohmann Therapie-Systeme AG for developing a ketamine microneedle patch; Alcami Corporation for the advancement of ketamine injectables and infusions; BioRAE, Inc. for the development of ketamine pump technology; Revive Therapeutics Ltd. to develop a psilocybin microneedle patch; and Gesval S.A. for the development of patented continuous-flow process technology for synthesizing ketamine and its analogs. PharmaTher is also internally dedicated to creating its own proprietary wearable ketamine delivery system, intended for addressing mental health, neurological, and pain conditions. Established in 2019, the company maintains its headquarters in Toronto, Canada.
Technical Analysis
COSCIENS Biopharma
―
Kane Biotech
―
BetterLife Pharma
―
BioVaxys Technology
―
Marvel Biosciences Corp
―
Options Prices
Currently, No data available
---